Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer.
Burce Isik, Matthew G Davey, Alisha A Jaffer, Juliette Buckley, Chwanrow Baban, Bridget Anne Merrigan, Shona Tormey
{"title":"Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer.","authors":"Burce Isik, Matthew G Davey, Alisha A Jaffer, Juliette Buckley, Chwanrow Baban, Bridget Anne Merrigan, Shona Tormey","doi":"10.1007/s10549-025-07615-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is a paucity of data supporting the role of neutrophil-lymphocyte ratios (NLR) to determine clinicopathological parameters in patients being treated for primary breast cancer.</p><p><strong>Aims: </strong>To evaluate the association between pre-operative NLR and clinicopathological parameters in patients diagnosed with breast cancer.</p><p><strong>Methods: </strong>A retrospective cohort study was performed. This included consecutive patients indicated to undergo surgery for primary breast cancer at University Hospital Limerick between January 2010 and June 2017. NLR was expressed as a continuous variable. Univariable and multivariable linear regression analyses were used to determine the correlation between NLR and clinicopathological data. Data analytics was performed using SPSS v29.0.</p><p><strong>Results: </strong>673 patients met the inclusion criteria. Overall, the median preoperative NLR is 2.63 (standard deviation: 1.42). At univariable analysis, patient age (beta coefficient: 0.009, 95% confidence interval (CI) 0.001-0.017, P = 0.027), tumour size (beta coefficient: 0.013, 95% CI 0.005-0.021, P = 0.001), and human epidermal growth factor receptor-2 status (beta coefficient: - 0.370, 95% CI - 0.676-0.065, P = 0.017) were all predicted using NLR. However, at multivariable analysis, tumour size was the sole parameter predictable by NLR (beta coefficient: 0.011, 95% CI 0.002-0.019, P = 0.013).</p><p><strong>Conclusions: </strong>This study demonstrates that pre-operative NLR may serve as an independent predictor of tumour size in patients being treated with primary breast cancer. Ratification of these preliminary findings is warranted before robustly adopted into clinical practice.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07615-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: There is a paucity of data supporting the role of neutrophil-lymphocyte ratios (NLR) to determine clinicopathological parameters in patients being treated for primary breast cancer.
Aims: To evaluate the association between pre-operative NLR and clinicopathological parameters in patients diagnosed with breast cancer.
Methods: A retrospective cohort study was performed. This included consecutive patients indicated to undergo surgery for primary breast cancer at University Hospital Limerick between January 2010 and June 2017. NLR was expressed as a continuous variable. Univariable and multivariable linear regression analyses were used to determine the correlation between NLR and clinicopathological data. Data analytics was performed using SPSS v29.0.
Results: 673 patients met the inclusion criteria. Overall, the median preoperative NLR is 2.63 (standard deviation: 1.42). At univariable analysis, patient age (beta coefficient: 0.009, 95% confidence interval (CI) 0.001-0.017, P = 0.027), tumour size (beta coefficient: 0.013, 95% CI 0.005-0.021, P = 0.001), and human epidermal growth factor receptor-2 status (beta coefficient: - 0.370, 95% CI - 0.676-0.065, P = 0.017) were all predicted using NLR. However, at multivariable analysis, tumour size was the sole parameter predictable by NLR (beta coefficient: 0.011, 95% CI 0.002-0.019, P = 0.013).
Conclusions: This study demonstrates that pre-operative NLR may serve as an independent predictor of tumour size in patients being treated with primary breast cancer. Ratification of these preliminary findings is warranted before robustly adopted into clinical practice.
背景：在原发性乳腺癌患者中，中性粒细胞-淋巴细胞比率（NLR）决定临床病理参数的作用缺乏数据支持。目的：探讨乳腺癌患者术前NLR与临床病理参数的关系。方法：采用回顾性队列研究。这包括2010年1月至2017年6月期间在利默里克大学医院接受原发性乳腺癌手术的连续患者。NLR表示为连续变量。采用单变量和多变量线性回归分析确定NLR与临床病理资料的相关性。使用SPSS v29.0进行数据分析。结果：673例患者符合纳入标准。总体而言，术前NLR中位数为2.63（标准差：1.42）。在单变量分析中，患者年龄（β系数：0.009,95%可信区间（CI） 0.001-0.017, P = 0.027）、肿瘤大小（β系数：0.013,95% CI 0.005-0.021, P = 0.001）和人表皮生长因子受体-2状态（β系数：- 0.370,95% CI - 0.676-0.065, P = 0.017）均使用NLR预测。然而，在多变量分析中，肿瘤大小是NLR可预测的唯一参数（β系数：0.011,95% CI 0.002-0.019, P = 0.013）。结论：本研究表明，术前NLR可作为原发性乳腺癌患者肿瘤大小的独立预测因子。这些初步发现的批准是有必要的，然后大力采用到临床实践。
期刊介绍：
Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
